A third report about ARCHER 1050 further confirmed that the OS benefit from first-line treatment with dacomitinib versus gefitinib is maintained after extended follow-up (47.9 months) in patients with advanced NSCLC with EGFR-activating mutations [59]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.